Follow the ANAPTYSBIO, INC. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.3bn. The latest transaction was disclosed on 13 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: DENNIS MULROY. All data is free.
16
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate ANAPTYSBIO, INC. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
19Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,813 of 29,063 companies
14.8
score / 100
Value
24
Quality
6
FCF yld-3.8%
Earn yld-4.8%
EV/EBITDA·
ROE-40%
Gross mgn·
Net mgn-55%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
20,000 shares@ US$51.65488.0% of flowCommonSEC144:0001950047-26-005511
16 of 16 declarations
Acerca de ANAPTYSBIO, INC.
ANAPTYSBIO, INC. es una empresa biofarmacéutica centrada en el desarrollo de terapias basadas en anticuerpos para enfermedades autoinmunes y cáncer. Cotiza en NASDAQ bajo el ticker ANAB.